Rojymon Jacob
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rojymon Jacob has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Akshita Khosla
Department of Hematology and Oncology, Louisiana State University, New Orleans, LA 70112, USA
2 shared publications - George M. Varghese
Department of Cardiovascular Medicine, Stanford University, Stanford, CA 94305, USA
2 shared publications - Gina Vaccaro
Tennessee Oncology, Nashville, Tennessee, USA
2 shared publications - Khwaja Saad Haq
Resident, Department of Internal Medicine, Wellstar Spalding Medical Center, Griffin, Georgia, USA
2 shared publications - Nithya Krishnakumaran
Department of Internal Medicine, Southeast Health Dothan, Dothan, AL 36301, USA
2 shared publications - Teresa M. Varghese
Resident, Department of Internal Medicine, Wellstar Spalding Medical Center, Griffin, Georgia
2 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9990
Benzyl Isothiocyanate Pretreatment Enhances Chemoradiation Response in HPV-Negative Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) accounts for ~3% of U.S. cancer diagnoses, and many patients present with locally or regionally advanced disease. Despite multimodal standard-of-care (SOC) treatment, the median overall survival for recurrent or metastatic disease remains ~12 months. Acquired resistance to cisplatin (CDDP) and radiotherapy (RT) remains a central barrier to durable response, motivating neoadjuvant strategies to improve efficacy in resistant tumors. Benzyl isothiocyanate (BITC) is a dietary phytochemical with selective anticancer activity. Across four patient-matched HNSCC cell lines spanning a range of intrinsic sensitivities to CDDP or RT, pretreatment with BITC before RT and CDDP significantly increased HNSCC cell death as measured by caspase-3/7 activity, regardless of each cell line’s single-agent sensitivity. Within 24 h, BITC elevated cytoplasmic ROS across all lines: BITC-resistant cell lines countered this with a more robust increase in the GSH/GSSG ratio and retained viability, whereas the BITC-sensitive lines mounted a weaker glutathione (GSH) response and required rescue with exogenous GSH or N-acetylcysteine (NAC), indicating redox-sensitive cytotoxicity. Transcriptomic time-course analysis suggested that BITC induces a coordinated stress response, including proteotoxic HSF1 activation, and suppresses DNA replication and homologous recombination repair, thereby supporting a transcriptional basis for the observed sensitization to DNA-damaging therapy. By enhancing the efficacy of RT and CDDP in HPV-negative HNSCC, BITC may be a promising neoadjuvant strategy to improve the therapeutic index of chemotherapy and radiation in these patients, warranting further investigation.
- 7 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9990
Open AccessBenzyl Isothiocyanate Pretreatment Enhances Chemoradiation Response in HPV-Negative Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) accounts for ~3% of U.S. cancer diagnoses, and many patients present with locally or regionally advanced disease. Despite multimodal standard-of-care (SOC) treatment, the median overall survival for recurrent or metastatic disease remains ~12 months. Acquired resistance to cisplatin (CDDP) and radiotherapy (RT) remains a central barrier to durable response, motivating neoadjuvant strategies to improve efficacy in resistant tumors. Benzyl isothiocyanate (BITC) is a dietary phytochemical with selective anticancer activity. Across four patient-matched HNSCC cell lines spanning a range of intrinsic sensitivities to CDDP or RT, pretreatment with BITC before RT and CDDP significantly increased HNSCC cell death as measured by caspase-3/7 activity, regardless of each cell line’s single-agent sensitivity. Within 24 h, BITC elevated cytoplasmic ROS across all lines: BITC-resistant cell lines countered this with a more robust increase in the GSH/GSSG ratio and retained viability, whereas the BITC-sensitive lines mounted a weaker glutathione (GSH) response and required rescue with exogenous GSH or N-acetylcysteine (NAC), indicating redox-sensitive cytotoxicity. Transcriptomic time-course analysis suggested that BITC induces a coordinated stress response, including proteotoxic HSF1 activation, and suppresses DNA replication and homologous recombination repair, thereby supporting a transcriptional basis for the observed sensitization to DNA-damaging therapy. By enhancing the efficacy of RT and CDDP in HPV-negative HNSCC, BITC may be a promising neoadjuvant strategy to improve the therapeutic index of chemotherapy and radiation in these patients, warranting further investigation.
- Open Access
Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database
Background: Cholangiocarcinoma, malignancies arising from the intrahepatic and extrahepatic bile ducts, has increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in specific racial groups such as Asian and Pacific Islander patients. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African American, Hispanic, Asian or Pacific Islander, Native American, and Other. The data analysis was performed using STATA/BE version 18.5. Univariable and multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were White, 13.27% Hispanic, and 10.13% African American. There was a statistically significant difference in gender distribution across racial groups (p < 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among the Hispanic group. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p < 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African American, Native American, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.
Open AccessImpact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database
Background: Cholangiocarcinoma, malignancies arising from the intrahepatic and extrahepatic bile ducts, has increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in specific racial groups such as Asian and Pacific Islander patients. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African American, Hispanic, Asian or Pacific Islander, Native American, and Other. The data analysis was performed using STATA/BE version 18.5. Univariable and multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were White, 13.27% Hispanic, and 10.13% African American. There was a statistically significant difference in gender distribution across racial groups (p < 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among the Hispanic group. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p < 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African American, Native American, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.
- Open Access
- 11 June 2025
- Published by MDPI AG in Preprints.org
Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database
Background: Cholangiocarcinoma, malignancies arising from intrahepatic and extrahepatic bile ducts, have increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in certain racial groups such as Asian and Pacific Islanders. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African Americans, Hispanics, Asian or Pacific Islanders, Native Americans, and Others. The data analysis was performed using STATA/BE version 18.5. Univariate and Multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were Whites, 13.27% Hispanics, and 10.13% African-Americans. There was a statistically significant difference in gender distribution across racial groups (p< 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among Hispanics. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African-American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p< 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African Americans, Native Americans, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.
- 11 June 2025
- Published by MDPI AG in Preprints.org
Open AccessImpact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database
Background: Cholangiocarcinoma, malignancies arising from intrahepatic and extrahepatic bile ducts, have increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in certain racial groups such as Asian and Pacific Islanders. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African Americans, Hispanics, Asian or Pacific Islanders, Native Americans, and Others. The data analysis was performed using STATA/BE version 18.5. Univariate and Multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were Whites, 13.27% Hispanics, and 10.13% African-Americans. There was a statistically significant difference in gender distribution across racial groups (p< 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among Hispanics. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African-American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p< 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African Americans, Native Americans, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.